MedTrace Logo

A Study to Investigate Efficacy, Tolerability and Safety of ABY-035 in Patients With Active Psoriatic Arthritis

NCT04713072 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 129

Last updated 2024-02-09

No results posted yet for this study

Summary

This is a Phase II, prospective, multicenter, randomized, double-blind, placebo-controlled, dose finding trial in parallel-groups with primary endpoint at Week 16 (visit V9) to investigate the efficacy, tolerability, safety, pharmacokinetics and immunogenicity of ABY-035 in adult patients with PsA.

Conditions

Interventions

BIOLOGICAL

ABY-035

ABY-035 solution for injection

BIOLOGICAL

Placebo

Placebo to ABY-035 solution for injection

Sponsors & Collaborators

  • ACELYRIN Inc.

    lead INDUSTRY

Principal Investigators

  • Myreen Tomas, MD · ACELYRIN Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-04
Primary Completion
2021-10-01
Completion
2022-01-27

Countries

  • Austria
  • Belgium
  • Czechia
  • Germany
  • Hungary
  • Poland
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04713072 on ClinicalTrials.gov